Lantheus to be acquired by Curium for up to $8.0 billion
Lantheus Holdings announced a definitive agreement to merge with Curium US Holding, an affiliate of Curium, for up to $114.50 per share, creating a radiopharmaceutical company focused on diagnostics and therapeutics.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day